Open AccessAssociation of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer
Author(s) -
Tarek M. Abdel-Fatah,
Graham Ball,
Pulari U. Thangavelu,
Lynne Reid,
Amy E. McCart Reed,
Jodi M. Saunus,
Pascal H. G. Duijf,
Peter T. Simpson,
Sunil R. Lakhani,
Lőrinc Sándor Pongor,
Balázs Győrffy,
Paul M. Moseley,
Andrew R. Green,
A. Graham Pockley,
Carlos Caldas,
Ian O. Ellis,
Stephen Chan
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.9486
Subject(s) - breast cancer , medicine , oncology , estrogen receptor , estrogen , neoadjuvant therapy , cancer , anthracycline , gynecology
Key Points Question Are sperm-associated antigen 5 ( SPAG5 ) transcript or protein expressions associated with treatment response in patients with estrogen receptor–positive breast cancer? Findings In this cohort study including 12 720 patients with estrogen receptor–positive breast cancer, SPAG5 transcript and SPAG5 protein overexpressions were associated with worse outcomes in patients who received endocrine therapy alone. Overexpressions of SPAG5 transcript or SPAG5 protein were associated with resistance to endocrine therapy but sensitivity to anthracycline-based combination chemotherapy, and downregulation of SPAG5 during the course of preoperative systemic therapies was associated with clinical benefit. Meaning These findings suggest that SPAG5 transcript or SPAG5 protein expression could be used as a clinical tool for selecting and monitoring response to neoadjuvant therapies and guide adjuvant therapy in estrogen receptor–positive breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom